Mainz Biomed and Praxisdienst Form Distribution Alliance for ColoAlert
BERKELEY, US – MAINZ, Germany – February 23, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is pleased to announce a distribution partnership with Praxisdienst, Germany’s largest online retailer for medical products. This collaboration, which commenced in February 2024, marks an important step in Mainz Biomed’s mission to enhance healthcare delivery across Germany, focusing on the accessibility of their flagship product, ColoAlert®.
ColoAlert® represents a breakthrough in the early detection of colorectal cancer, offering a convenient, non-invasive at-home stool test that goes beyond traditional screening methods. Unlike standard tests that only detect the presence of blood in the stool, ColoAlert® utilizes advanced technology to identify tumor DNA, providing a more comprehensive screening option. This innovative approach ensures higher detection rates, especially in cases where tumors do not bleed, thereby facilitating the early diagnosis of colorectal cancer. Early detection is crucial, as it significantly enhances the treatability of this condition, potentially saving lives.
Praxisdienst, has consistently demonstrated its capacity for innovation and leadership in the medical products market. Praxisdienst’s achievements, including the “Deutscher Gesundheits-Award 2022” in the “Medical Technology – Online Shops” category and its recognition as a Top Innovator in 2023, highlight its dedication to excellence and innovation.
This partnership will harness Praxisdienst’s extensive distribution network alongside Mainz Biomed’s leading-edge diagnostic technologies, ensuring broader access to their sophisticated medical solutions for healthcare professionals and patients throughout Germany.
Darin Leigh, CCO of Mainz Biomed, expressed enthusiasm about the partnership: “We are delighted to partner with Praxisdienst to distribute ColoAlert®, our innovative at-home screening test for colorectal cancer. This collaboration is not only in line with our strategic objectives but also underscores our commitment to providing superior diagnostic solutions to the healthcare sector. We are confident that this partnership will have a profound impact on healthcare standards and patient care in Germany by making early detection of colorectal cancer more accessible.”